Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06571162 · ClinicalTrials.gov registry record · NA
A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients
A NA study of Atherosclerotic Cardiovascular Disease, sponsored by Intermountain Health Care.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT06571162: Recruiting NA study of Atherosclerotic Cardiovascular Disease, sponsored by Intermountain Health Care.
NCT06571162 is a NA study of Atherosclerotic Cardiovascular Disease that is actively recruiting participants, run by Intermountain Health Care. The registered enrollment target is 400 participants, below the 7,549-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06571162, a NA study of Atherosclerotic Cardiovascular Disease, is actively recruiting participants, sponsored by Intermountain Health Care.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \<70 mg/dL by increasing statin and/or LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.
Conditions Studied
Interventions
- OTHER Usual Care
- OTHER Clinical Pharmacy Team
Study Locations (1)
Utah
- Intermountain Healthcare Hospitals and Clinics - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2028-09 |
| Phase | NA |
What NCT06571162 shows while recruiting
NCT06571162 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 7,549-participant average among 21 other Atherosclerotic Cardiovascular Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Atherosclerotic Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT06571162 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06571162 about?
NCT06571162 is a clinical study titled "A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients". Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receivi...
What is the current status of trial NCT06571162?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2025-01-30. Estimated completion is 2028-09.
What conditions does trial NCT06571162 study?
This clinical trial studies the following conditions: Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT06571162?
The interventions under investigation include: Usual Care (OTHER), Clinical Pharmacy Team (OTHER).
Who is sponsoring clinical trial NCT06571162?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06571162 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerotic Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06571162's enrollment target sits among peer trials
400 12th of 21 higher than 10 of 21 other Atherosclerotic Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerotic Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
RECRUITING · NA
-
The Young Heart Study
ACTIVE NOT RECRUITING · NA
-
Behavioral Economic Approaches to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease
COMPLETED · NA
-
A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
COMPLETED · NA
-
Recipe for Heart Health
COMPLETED · NA
-
Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI